RAPP
Rapport Therapeutics, Inc. Common Stock
Biotechnology
Market Cap$1.46B
5Y Perf.+71.7%
Compare Stocks
3 / 10Try these comparisons:
Stock Comparison
RAPP vs PTCT vs ACAD
Revenue, margins, valuation, and 5-year total return — side by side.
PTCT
PTC Therapeutics, Inc.
Biotechnology
Market Cap$5.35B
5Y Perf.+110.9%
ACAD
ACADIA Pharmaceuticals Inc.
Biotechnology
Market Cap$3.86B
5Y Perf.+38.9%
RAPP vs PTCT vs ACAD — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | RAPP | PTCT | ACAD |
|---|---|---|---|
| Industry | Biotechnology | Biotechnology | Biotechnology |
| Market Cap | $1.46B | $5.35B | $3.86B |
| Revenue (TTM) | $20M | $827M | $1.10B |
| Net Income (TTM) | $-107M | $-187M | $376M |
| Gross Margin | -1.3% | 49.7% | 91.5% |
| Operating Margin | -6.1% | -8.3% | 7.4% |
| Forward P/E | — | 8.3x | 50.9x |
| Total Debt | $11M | $492M | $52M |
| Cash & Equiv. | $53M | $985M | $178M |
RAPP vs PTCT vs ACAD — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
RAPP
PTCT
ACAD
| Stock | Jun 24 | May 26 | Return |
|---|---|---|---|
| Rapport Therapeutic… (RAPP) | 100 | 171.7 | +71.7% |
| PTC Therapeutics, I… (PTCT) | 100 | 210.9 | +110.9% |
| ACADIA Pharmaceutic… (ACAD) | 100 | 138.9 | +38.9% |
Price return only. Dividends and distributions are not included.
Quick Verdict: RAPP vs PTCT vs ACAD
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: PTCT leads in 3 of 7 categories, making it the strongest pick for growth and revenue expansion and valuation and capital efficiency. ACADIA Pharmaceuticals Inc. is the stronger pick specifically for profitability and margin quality and operational efficiency and capital deployment. As sector peers, any of these can serve as alternatives in the same allocation.
RAPP
Rapport Therapeutics, Inc. Common Stock
The Defensive Pick
RAPP is the clearest fit if your priority is sleep-well-at-night.
- Lower volatility, beta 1.55, Low D/E 2.4%, current ratio 26.17x
- +290.7% vs ACAD's +52.4%
Best for: sleep-well-at-night
PTCT
PTC Therapeutics, Inc.
The Income Pick
PTCT has the current edge in this matchup, primarily because of its strength in income & stability and growth exposure.
- beta 1.13
- Rev growth 114.5%, EPS growth 264.5%, 3Y rev CAGR 35.3%
- 7.3% 10Y total return vs RAPP's 92.0%
Best for: income & stability and growth exposure
ACAD
ACADIA Pharmaceuticals Inc.
The Quality Compounder
ACAD is the clearest fit if your priority is quality and efficiency.
- 34.3% margin vs RAPP's -5.4%
- 26.2% ROA vs RAPP's -23.4%, ROIC 10.0% vs -27.1%
Best for: quality and efficiency
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | PTCT | 114.5% revenue growth vs RAPP's -20.9% |
| Value | PTCT | Lower P/E (8.3x vs 50.9x) |
| Quality / Margins | ACAD | 34.3% margin vs RAPP's -5.4% |
| Stability / Safety | PTCT | Beta 1.13 vs RAPP's 1.55 |
| Dividends | Tie | None of these 3 stocks pay a meaningful dividend |
| Momentum (1Y) | RAPP | +290.7% vs ACAD's +52.4% |
| Efficiency (ROA) | ACAD | 26.2% ROA vs RAPP's -23.4%, ROIC 10.0% vs -27.1% |
RAPP vs PTCT vs ACAD — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2025
FY 2018
RAPP vs PTCT vs ACAD — Financial Metrics
Side-by-side numbers across 3 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLRAPPLAGGINGACAD
Who Leads Where
ACAD leads in 1 of 6 categories
PTCT leads 1 • RAPP leads 1 • 2 tied
Explore the data ↓ACADACADIA Pharmaceutical…
1leads
PTCTPTC Therapeutics, Inc.
1leads
RAPPRapport Therapeutics,…
1leads
6 Total Categories
CATEGORYLEADERvs PTCTvs ACADMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
ACAD5/6
Valuation MetricsMultiples, price ratios, and targets
PTCT3/5
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
Tied
—
Total Returns1Y, 3Y, 5Y total returns with dividends
RAPP5/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
ACAD leads this category, winning 5 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
ACAD is the larger business by revenue, generating $1.1B annually — 54.8x RAPP's $20M. ACAD is the more profitable business, keeping 34.3% of every revenue dollar as net income compared to RAPP's -5.4%. On growth, ACAD holds the edge at +9.7% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | RAPPRapport Therapeut… | PTCTPTC Therapeutics,… | ACADACADIA Pharmaceut… |
|---|---|---|---|
| RevenueTrailing 12 months | $20M | $827M | $1.1B |
| EBITDAEarnings before interest/tax | -$121M | -$37M | $96M |
| Net IncomeAfter-tax profit | -$107M | -$187M | $376M |
| Free Cash FlowCash after capex | -$80M | -$229M | $212M |
| Gross MarginGross profit ÷ Revenue | -1.3% | +49.7% | +91.5% |
| Operating MarginEBIT ÷ Revenue | -6.1% | -8.3% | +7.4% |
| Net MarginNet income ÷ Revenue | -5.4% | -22.6% | +34.3% |
| FCF MarginFCF ÷ Revenue | -4.0% | -27.7% | +19.4% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | -76.8% | +9.7% |
| EPS Growth (YoY)Latest quarter vs prior year | +38.2% | -100.3% | -81.8% |
ACAD leads this category, winning 5 of 6 comparable metrics.
Valuation Metrics
PTCT leads this category, winning 3 of 5 comparable metrics.
Valuation Metrics
At 8.3x trailing earnings, PTCT trades at a 16% valuation discount to ACAD's 9.9x P/E. On an enterprise value basis, PTCT's 5.4x EV/EBITDA is more attractive than ACAD's 26.9x.
| Metric | RAPPRapport Therapeut… | PTCTPTC Therapeutics,… | ACADACADIA Pharmaceut… |
|---|---|---|---|
| Market CapShares × price | $1.5B | $5.3B | $3.9B |
| Enterprise ValueMkt cap + debt − cash | $1.4B | $4.9B | $3.7B |
| Trailing P/EPrice ÷ TTM EPS | -13.96x | 8.29x | 9.85x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — | 50.91x |
| PEG RatioP/E ÷ EPS growth rate | — | — | — |
| EV / EBITDAEnterprise value multiple | — | 5.42x | 26.91x |
| Price / SalesMarket cap ÷ Revenue | — | 3.09x | 3.61x |
| Price / BookPrice ÷ Book value/share | 3.87x | — | 3.15x |
| Price / FCFMarket cap ÷ FCF | — | 7.61x | 36.74x |
PTCT leads this category, winning 3 of 5 comparable metrics.
Profitability & Efficiency
Evenly matched — PTCT and ACAD each lead in 3 of 8 comparable metrics.
Profitability & Efficiency
ACAD delivers a 35.6% return on equity — every $100 of shareholder capital generates $36 in annual profit, vs $-25 for RAPP. RAPP carries lower financial leverage with a 0.02x debt-to-equity ratio, signaling a more conservative balance sheet compared to ACAD's 0.04x. On the Piotroski fundamental quality scale (0–9), PTCT scores 7/9 vs RAPP's 2/9, reflecting strong financial health.
| Metric | RAPPRapport Therapeut… | PTCTPTC Therapeutics,… | ACADACADIA Pharmaceut… |
|---|---|---|---|
| ROE (TTM)Return on equity | -24.8% | — | +35.6% |
| ROA (TTM)Return on assets | -23.4% | -6.8% | +26.2% |
| ROICReturn on invested capital | -27.1% | — | +10.0% |
| ROCEReturn on capital employed | -31.3% | +55.9% | +10.1% |
| Piotroski ScoreFundamental quality 0–9 | 2 | 7 | 6 |
| Debt / EquityFinancial leverage | 0.02x | — | 0.04x |
| Net DebtTotal debt minus cash | -$41M | -$492M | -$126M |
| Cash & Equiv.Liquid assets | $53M | $985M | $178M |
| Total DebtShort + long-term debt | $11M | $492M | $52M |
| Interest CoverageEBIT ÷ Interest expense | — | -1.67x | — |
Evenly matched — PTCT and ACAD each lead in 3 of 8 comparable metrics.
Total Returns (Dividends Reinvested)
RAPP leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in RAPP five years ago would be worth $19,197 today (with dividends reinvested), compared to $10,710 for ACAD. Over the past 12 months, RAPP leads with a +290.7% total return vs ACAD's +52.4%. The 3-year compound annual growth rate (CAGR) favors RAPP at 24.3% vs ACAD's 1.5% — a key indicator of consistent wealth creation.
| Metric | RAPPRapport Therapeut… | PTCTPTC Therapeutics,… | ACADACADIA Pharmaceut… |
|---|---|---|---|
| YTD ReturnYear-to-date | +42.0% | -16.0% | -13.7% |
| 1-Year ReturnPast 12 months | +290.7% | +58.2% | +52.4% |
| 3-Year ReturnCumulative with dividends | +92.0% | +16.1% | +4.7% |
| 5-Year ReturnCumulative with dividends | +92.0% | +60.3% | +7.1% |
| 10-Year ReturnCumulative with dividends | +92.0% | +733.2% | -22.9% |
| CAGR (3Y)Annualised 3-year return | +24.3% | +5.1% | +1.5% |
RAPP leads this category, winning 5 of 6 comparable metrics.
Risk & Volatility
Evenly matched — RAPP and PTCT each lead in 1 of 2 comparable metrics.
Risk & Volatility
PTCT is the less volatile stock with a 1.13 beta — it tends to amplify market swings less than RAPP's 1.55 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. RAPP currently trades 94.5% from its 52-week high vs PTCT's 73.7% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | RAPPRapport Therapeut… | PTCTPTC Therapeutics,… | ACADACADIA Pharmaceut… |
|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.55x | 1.13x | 1.26x |
| 52-Week HighHighest price in past year | $42.27 | $87.50 | $27.81 |
| 52-Week LowLowest price in past year | $7.73 | $37.94 | $14.45 |
| % of 52W HighCurrent price vs 52-week peak | +94.5% | +73.7% | +81.1% |
| RSI (14)Momentum oscillator 0–100 | 61.9 | 45.3 | 44.2 |
| Avg Volume (50D)Average daily shares traded | 335K | 1.0M | 1.8M |
Evenly matched — RAPP and PTCT each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: RAPP as "Buy", PTCT as "Buy", ACAD as "Buy". Consensus price targets imply 54.1% upside for ACAD (target: $35) vs 22.7% for RAPP (target: $49).
| Metric | RAPPRapport Therapeut… | PTCTPTC Therapeutics,… | ACADACADIA Pharmaceut… |
|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | $49.00 | $89.67 | $34.78 |
| # AnalystsCovering analysts | 5 | 26 | 37 |
| Dividend YieldAnnual dividend ÷ price | — | — | — |
| Dividend StreakConsecutive years of raises | — | — | — |
| Dividend / ShareAnnual DPS | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
ACAD leads in 1 of 6 categories (Income & Cash Flow). PTCT leads in 1 (Valuation Metrics). 2 tied.
Best OverallRapport Therapeutics, Inc. … (RAPP)Leads 1 of 6 categories
Loading custom metrics...
RAPP vs PTCT vs ACAD: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is RAPP or PTCT or ACAD a better buy right now?
For growth investors, PTC Therapeutics, Inc.
(PTCT) is the stronger pick with 114. 5% revenue growth year-over-year, versus 11. 9% for ACADIA Pharmaceuticals Inc. (ACAD). PTC Therapeutics, Inc. (PTCT) offers the better valuation at 8. 3x trailing P/E, making it the more compelling value choice. Analysts rate Rapport Therapeutics, Inc. Common Stock (RAPP) a "Buy" — based on 5 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — RAPP or PTCT or ACAD?
On trailing P/E, PTC Therapeutics, Inc.
(PTCT) is the cheapest at 8. 3x versus ACADIA Pharmaceuticals Inc. at 9. 9x.
03Which is the better long-term investment — RAPP or PTCT or ACAD?
Over the past 5 years, Rapport Therapeutics, Inc.
Common Stock (RAPP) delivered a total return of +92. 0%, compared to +7. 1% for ACADIA Pharmaceuticals Inc. (ACAD). Over 10 years, the gap is even starker: PTCT returned +733. 2% versus ACAD's -22. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — RAPP or PTCT or ACAD?
By beta (market sensitivity over 5 years), PTC Therapeutics, Inc.
(PTCT) is the lower-risk stock at 1. 13β versus Rapport Therapeutics, Inc. Common Stock's 1. 55β — meaning RAPP is approximately 37% more volatile than PTCT relative to the S&P 500. On balance sheet safety, Rapport Therapeutics, Inc. Common Stock (RAPP) carries a lower debt/equity ratio of 2% versus 4% for ACADIA Pharmaceuticals Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — RAPP or PTCT or ACAD?
By revenue growth (latest reported year), PTC Therapeutics, Inc.
(PTCT) is pulling ahead at 114. 5% versus 11. 9% for ACADIA Pharmaceuticals Inc. (ACAD). On earnings-per-share growth, the picture is similar: PTC Therapeutics, Inc. grew EPS 264. 5% year-over-year, compared to 24. 3% for Rapport Therapeutics, Inc. Common Stock. Over a 3-year CAGR, PTCT leads at 35. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — RAPP or PTCT or ACAD?
PTC Therapeutics, Inc.
(PTCT) is the more profitable company, earning 39. 4% net margin versus -536. 4% for Rapport Therapeutics, Inc. Common Stock — meaning it keeps 39. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: PTCT leads at 49. 5% versus -611. 0% for RAPP. At the gross margin level — before operating expenses — PTCT leads at 95. 9%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is RAPP or PTCT or ACAD more undervalued right now?
Analyst consensus price targets imply the most upside for ACAD: 54.
1% to $34. 78.
08Which pays a better dividend — RAPP or PTCT or ACAD?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
09Is RAPP or PTCT or ACAD better for a retirement portfolio?
For long-horizon retirement investors, PTC Therapeutics, Inc.
(PTCT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 13), +733. 2% 10Y return). Rapport Therapeutics, Inc. Common Stock (RAPP) carries a higher beta of 1. 55 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (PTCT: +733. 2%, RAPP: +92. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between RAPP and PTCT and ACAD?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: RAPP is a small-cap quality compounder stock; PTCT is a small-cap high-growth stock; ACAD is a small-cap deep-value stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.